Prognosis Clinical Trials
2 recruiting trials for Prognosis. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Prognosis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Peking University Third Hospital (1), Chinese PLA General Hospital (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Model-guided adjuvant treatment (procedure, 1 trial), followed by No adjuvant treatment, Cardiac Magnetic Resonance Imaging (CMR).
Track Prognosis trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Validation of RCC Predicting Model With Emulated-target Trial
This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a...
Using Cardiac MRI to Predict Outcomes in Patients With STEMI
This prospective, multicenter observational study aims to evaluate the prognostic value of a comprehensive set of cardiac magnetic resonance (CMR) imaging parameters in patients...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Prognosis, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Prognosis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Prognosis, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.